Data from Pharmawand - Curated by Marshall Pearce - Date added 28 November 2017

Regeneron Pharmaceuticals, Inc. announced that results from two Phase II studies that added the angiopoietin2 (Ang2) antibody nesvacumab to Eylea (aflibercept) Injection did not provide sufficient differentiation to warrant Phase III development.

The RUBY study evaluated patients with diabetic macular edema (DME) and the ONYX study evaluated patients with wet age-related macular degeneration (wet AMD). EYLEA results were consistent with findings in previous clinical studies. There were no new safety signals in these studies. RUBY and ONYX were two, randomized, double-masked, active-controlled phase II studies designed to investigate if a combination of aflibercept and nesvacumab offered additional benefit over aflibercept monotherapy. The studies evaluated two different doses of nesvacumab in combination with aflibercept, both administered as a single co-formulated intravitreal injection, as well as aflibercept monotherapy. The primary endpoint for both trials was change in best-corrected visual acuity (BCVA) between week 12 and 36 as measured by the Early Treatment Diabetic Retinopathy Study (ETDRS) letter score.

Results from RUBY and ONYX will be further analyzed and will be submitted for presentation at a future medical congress. The combination of aflibercept and nesvacumab is being jointly developed by Regeneron and Bayer AG under a global collaboration agreement. The safety and efficacy of the potential use of a co-formulated combination of aflibercept and nesvacumab in wet AMD and DME have not been fully evaluated by any regulatory authority.

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

+ 3 more

Bedwetting

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting.

+ 7 more

Type 2 Diabetes

Type 2 Diabetes

View the latest epidemiology data, patient perspectives, ADA and EASD recommendations, treatment options and more.

Load more

Related Content